Low Post-Treatment Recurrence After a Shortened All-oral Regimen for Pulmonary Rifampicin- or Multidrug-Resistant Tuberculosis in Individuals without Prior Second-Line Drug Exposure in Kazakhstan.

Authors

Edmund Shen, Yerkebulan Algozhin, Letizia Trevisi, Allison LaHood, Elena Algozhina, Nataliya Arlyapova, Kwonjune Justin Seung, Carole D Mitnick, Michael L Rich, Molly F Franke, Makhmujan Rashitov

Published in

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Jul 01, 2026. Epub Jul 01, 2026.

Abstract

We conducted a prospective cohort study of adults with pulmonary MDR/RR-TB in Kazakhstan treated with one of three all-oral, five-drug regimens. Individuals were followed microbiologically and clinically for up to 12 months post-treatment. Of 578 with favorable end-of-treatment outcomes, we observed only one incident case of recurrent TB (0.2%, 95%CI: 0.0-1.0%), suggesting excellent regimen durability under programmatic conditions.

PMID:
42383496
Bibliographic data and abstract were imported from PubMed on 01 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.